January 4, 2017 / 2:26 PM / 8 months ago

BRIEF-Cytrx granted type b pre-nda meeting with U.S. FDA for registration pathway with aldoxorubicin

Jan 4 (Reuters) - Cytrx Corp :

* Cytrx granted type b pre-nda meeting with U.S. FDA for registration pathway with aldoxorubicin as a treatment for patients with relapsed soft tissue sarcomas

* Cytrx Corp- cytrx expects overall survival data to be available in 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below